Searched for
EMCURE LABORATORIES
Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- War-proof stocks: Why 45 names soared even as Iran-US conflict caused mayhem in Indian stock marketIndian stocks are defying global market fears. Pharma, energy, and industrial companies are delivering positive returns. Investors are favo...
- GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy genericsIndian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...
- Novo to track generic surge as semaglutide goes off patentNovo Nordisk is preparing for a surge of generic semaglutide drugs in India. The company's India head stated they will monitor rivals' pric...
- Companies offer "holistic support" to candidates under PM Internship scheme: MCAA pilot project of the PM Internship scheme has launched, with youths from 656 districts across India starting internships at various compa...
- Stock market update: Nifty Pharma index advances 0.55%The Nifty Pharma index closed 0.55 per cent up at 20755.35.
- IPO Calendar: Primary market gears up for another robust week as 3 companies look to raise Rs 2,700 crApart from the above 3 public offers, the Street will see as many 11 listings including that of Allied Blenders and Vraj Iron and Steel, wh...
- Emcure to soon file papers for Rs 4,000 crore IPOThe IPO will consist of a primary issue and offer for sale from its promoter Satish Mehta and existing investor Bain Capital which acquired...
- Generics company Emcure plans Rs 4,000 crore IPOEmcure may appoint as many as six bankers for the IPO including JM Financial, Kotak Capital, Axis Capital and SBI Capital, the people said....
- Emcure to launch generic breast cancer medicineEribulin, sold by Japanese drug maker Eisai under brand name Halaven, is used to treat HER 2 negative patients. It costs Rs 5,000 per vial.
- Pharma stocks soar despite US lawsuitAmong other listed stocks out of the five, Cadila Healthcare gained 2.87 per cent at Rs 512 at around the same time.
- US states sue 5 Indian generic drug makers over price cartelisationThe new lawsuit has also named some individual executives, including Rajiv Malik, president of Mylan, and Satish Mehta, MD of Emcure Pharma.
- Alkem Lab approaches SEBI to raise Rs 1,500-3,500 crore via IPOAlkem Laboratories filed draft papers with capital markets regulator Sebi to raise an estimated Rs 1,500-3,500 crore through an IPO.
- Shares of Sun Pharma, Ranbaxy rise after regulatory nods for merger dealAt end of trade, Sun Pharmaceutical Industries ended at Rs 1,039.85, up 1.55 per cent and Ranbaxy Laboratories closed at Rs 819.55 apiece, ...
- Sun-Ranbaxy $4 billion merger completedSun Pharmaceutical Industries today said merger of Ranbaxy with itself has been 'consummated' following receipt of requisite approvals.
- Sun Pharma gets RBI nod for transfer of Ranbaxy's overseas investmentsThe central bank also approved issue of equity shares of Sun Pharma to the non-resident holders of equity shares of Ranbaxy Laboratories, t...
- Sun-Ranbaxy deal gets final CCI nod; Emcure to buy 7 brandsThis clears the way for creating the biggest drug company in India with a market share of 9% and the fifth largest generic drug firm in the...
- Pharma MNCs GSK, Merck, Pfizer and others prefer tie-ups over acquisitions with Indian firmsWith Indian drug makers flooding the developed markets, GSK, Merck, Pfizer now prefer tie-ups over acquisitions with Indian players.
- Drug cos eye US entry after FDA checksThe US drug regulator has inspected the manufacturing plants of at least half-a-dozen Indian drugmakers, raising hopes that these companies...
Load More
